


## Azido-PEG8-PFP ester

<b>Cat. No.:</b>	HY-140773
<b>CAS No.:</b>	2055014-62-3
<b>Molecular Formula:</b>	C <sub>25</sub> H <sub>36</sub> F <sub>5</sub> N <sub>3</sub> O <sub>10</sub>
<b>Molecular Weight:</b>	633.56
<b>Target:</b>	PROTAC Linkers
<b>Pathway:</b>	PROTAC
<b>Storage:</b>	-20°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (157.84 mM; Need ultrasonic)					
		Solvent Concentration	Mass			
	<b>Preparing Stock Solutions</b>			1 mg	5 mg	10 mg
		1 mM		1.5784 mL	7.8919 mL	15.7838 mL
		5 mM		0.3157 mL	1.5784 mL	3.1568 mL
	10 mM		0.1578 mL	0.7892 mL	1.5784 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.5 mg/mL (3.95 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (3.95 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.5 mg/mL (3.95 mM); Clear solution</li> </ol>					

### BIOLOGICAL ACTIVITY

<b>Description</b>	Azido-PEG8-PFP ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs <sup>[1]</sup> . Azido-PEG8-PFP ester is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAC) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
<b>IC<sub>50</sub> &amp; Target</b>	PEGs
<b>In Vitro</b>	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for

---

the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA